Laurent Ducry
Research Subjects
Laurent Ducry has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Dominique M. Roberge
Chemical Manufacturing Technologies, Lonza AG, CH-3930 Visp, Switzerland
2 shared publications - Alain Beck
CIPF
1 shared publication - April Xu
Pfizer; Pearl River, NY USA
1 shared publication - Bernhard Stump
Lonza AG, Bioconjugates Development, Rottenstr., 3930 Visp, Switzerland
1 shared publication - Christine Klinguer-Hamour
Centre d'Immunologie Pierre Fabre, 5 Avenue Napoléon IIIBP 60497, 74164 Saint-Julien-en-Genevois, France
1 shared publication - Dhaval K. Shah
Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, USA
1 shared publication
Latest Publications
- Open Access
- 10 April 2015
- Published by InPress Media Group in ADC Review / Journal of Antibody-drug Conjugates
- Vol. 3 (4)
New Learning Makes ADC Development Less Empirical (Editorial)
- 10 April 2015
- Published by InPress Media Group in ADC Review / Journal of Antibody-drug Conjugates
- Vol. 3 (4)
Open AccessNew Learning Makes ADC Development Less Empirical (Editorial)
- Open Access
- 20 November 2013
- Published by Taylor & Francis in mAbs
- Vol. 6 (1) , 18-29
World Antibody-Drug Conjugate Summit, October 15–16, 2013, San Francisco, CA
The World Antibody-Drug Conjugate (WADC) Summits organized by Hanson Wade are currently the largest meetings fully dedicated to ADCs. The first global ADC Summit was organized in Boston in October 2010. Since 2011, two WADC are held every year in Frankfurt and San Francisco, respectively. The 2013 WADC San Francisco event was structured around plenary sessions with keynote speakers from AbbVie, Agensys, ImmunoGen, Immunomedics, Genentech, Pfizer and Seattle Genetics. Parallel tracks were also organized addressing ADC discovery, development and optimization of chemistry, manufacturing and control (CMC) issues. Discovery and process scientists, regulatory experts (US Food and Drug Administration), academics and clinicians were present, including representatives from biotechnology firms (Concortis, CytomX Therapeutics, Glykos, Evonik, Igenica, Innate Pharma, Mersana Therapeutics, Polytherics, Quanta Biodesign, Redwood Bioscience, Sutro Biopharma, SynAffix), pharmaceutical companies (Amgen, Genmab, Johnson and Johnson, MedImmune, Novartis, Progenics, Takeda) and contract research or manufacturing organizations (Baxter, Bayer, BSP Pharmaceuticals, Fujifilm/Diosynth, Lonza, Pierre Fabre Contract Manufacturing, Piramal, SAFC, SafeBridge).
- 20 November 2013
- Published by Taylor & Francis in mAbs
- Vol. 6 (1) , 18-29
Open AccessWorld Antibody-Drug Conjugate Summit, October 15–16, 2013, San Francisco, CA
The World Antibody-Drug Conjugate (WADC) Summits organized by Hanson Wade are currently the largest meetings fully dedicated to ADCs. The first global ADC Summit was organized in Boston in October 2010. Since 2011, two WADC are held every year in Frankfurt and San Francisco, respectively. The 2013 WADC San Francisco event was structured around plenary sessions with keynote speakers from AbbVie, Agensys, ImmunoGen, Immunomedics, Genentech, Pfizer and Seattle Genetics. Parallel tracks were also organized addressing ADC discovery, development and optimization of chemistry, manufacturing and control (CMC) issues. Discovery and process scientists, regulatory experts (US Food and Drug Administration), academics and clinicians were present, including representatives from biotechnology firms (Concortis, CytomX Therapeutics, Glykos, Evonik, Igenica, Innate Pharma, Mersana Therapeutics, Polytherics, Quanta Biodesign, Redwood Bioscience, Sutro Biopharma, SynAffix), pharmaceutical companies (Amgen, Genmab, Johnson and Johnson, MedImmune, Novartis, Progenics, Takeda) and contract research or manufacturing organizations (Baxter, Bayer, BSP Pharmaceuticals, Fujifilm/Diosynth, Lonza, Pierre Fabre Contract Manufacturing, Piramal, SAFC, SafeBridge).
- 24 May 2012
- Published by Springer Nature
- Vol. 899, 489-497
Challenges in the Development and Manufacturing of Antibody–Drug Conjugates
Advances in antibody–drug conjugates (ADCs) will permit sensitive discrimination between healthy and cancer cells. Promising clinical results generated much hope that this targeted prodrug therapy will offer more effective treatment options to patients. Manufacturing such highly potent biopharmaceuticals presents a series of unique challenges. Some specific skills required for the process development and production of ADCs are discussed. In addition to the accuracy and reliability needed to handle these potent and costly materials, coworker safety and equipment cleaning are of particular importance. The ideas and concepts shared in this article are based on the experience that Lonza has gained in the ADC field since 2004.
- 24 May 2012
- Published by Springer Nature
- Vol. 899, 489-497
Challenges in the Development and Manufacturing of Antibody–Drug Conjugates
Advances in antibody–drug conjugates (ADCs) will permit sensitive discrimination between healthy and cancer cells. Promising clinical results generated much hope that this targeted prodrug therapy will offer more effective treatment options to patients. Manufacturing such highly potent biopharmaceuticals presents a series of unique challenges. Some specific skills required for the process development and production of ADCs are discussed. In addition to the accuracy and reliability needed to handle these potent and costly materials, coworker safety and equipment cleaning are of particular importance. The ideas and concepts shared in this article are based on the experience that Lonza has gained in the ADC field since 2004.
- Top Cited Papers
- 21 September 2009
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 21 (1) , 5-13
Antibody−Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies
Antibody−drug conjugates (ADCs) combine the specificity of monoclonal antibodies (mAbs) with the potency of cytotoxic molecules, thereby taking advantage of the best characteristics of both components. Along with the development of the mAbs and cytotoxins, the design of chemical linkers to covalently bind these building blocks is making rapid progress but remains challenging. Recent advances have resulted in linkers having increased stability in the bloodstream while allowing efficient payload release within the tumor cell.
- 21 September 2009
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 21 (1) , 5-13
Top Cited PapersAntibody−Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies
Antibody−drug conjugates (ADCs) combine the specificity of monoclonal antibodies (mAbs) with the potency of cytotoxic molecules, thereby taking advantage of the best characteristics of both components. Along with the development of the mAbs and cytotoxins, the design of chemical linkers to covalently bind these building blocks is making rapid progress but remains challenging. Recent advances have resulted in linkers having increased stability in the bloodstream while allowing efficient payload release within the tumor cell.
- 8 December 2005
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 44 (48) , 7972-7975
Controlled Autocatalytic Nitration of Phenol in a Microreactor
- 8 December 2005
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 44 (48) , 7972-7975
Controlled Autocatalytic Nitration of Phenol in a Microreactor
- 8 December 2005
- Published by Wiley in Angewandte Chemie
- Vol. 117 (48) , 8186-8189
Controlled Autocatalytic Nitration of Phenol in a Microreactor
- 8 December 2005
- Published by Wiley in Angewandte Chemie
- Vol. 117 (48) , 8186-8189
Controlled Autocatalytic Nitration of Phenol in a Microreactor